Index | NYSE Arca Biotechnology |
Investment focus | Equity, United States, Health Care |
Fund size | GBP 6 m |
Total expense ratio | 0.60% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | No |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in GBP) | 17.98% |
Inception/ Listing Date | 27 May 2020 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | First Trust |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
Investment Advisor | First Trust Advisors L.P. |
Custodian Bank | The Bank of New York Mellon SA/NV (Dublin Branch) |
Revision Company | PwC |
Fiscal Year End | 31 December |
Swiss representative | Waystone Fund Services (Switzeland) SA |
Swiss paying agent | Banque Cantonale de Genève |
Germany | 30% tax rebate |
Switzerland | No ESTV Reporting |
Austria | Tax Reporting Fund |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | |
Securities lending | No |
Securities lending counterparty |
Alnylam Pharmaceuticals | 5.19% |
Corcept Therapeutics | 4.39% |
United Therapeutics Corp. | 4.36% |
Halozyme Therapeutics | 4.31% |
Vertex Pharmaceuticals, Inc. | 3.75% |
Biogen, Inc. | 3.72% |
Amgen, Inc. | 3.72% |
Regeneron Pharmaceuticals | 3.66% |
Natera | 3.64% |
argenx | 3.60% |
United States | 84.30% |
Ireland | 3.13% |
Germany | 2.95% |
Other | 9.62% |
Health Care | 90.38% |
Other | 9.62% |
YTD | +4.75% |
1 month | +5.10% |
3 months | +8.32% |
6 months | +13.67% |
1 year | +8.47% |
3 years | +5.73% |
5 years | - |
Since inception (MAX) | -2.99% |
2023 | -3.32% |
2022 | +6.81% |
2021 | -2.52% |
2020 | - |
Volatility 1 year | 17.98% |
Volatility 3 years | 22.69% |
Volatility 5 years | - |
Return per risk 1 year | 0.47 |
Return per risk 3 years | 0.08 |
Return per risk 5 years | - |
Maximum drawdown 1 year | -11.48% |
Maximum drawdown 3 years | -20.96% |
Maximum drawdown 5 years | - |
Maximum drawdown since inception | -29.26% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
Borsa Italiana | EUR | FBT | FBT IM FBTINAV | FBT.MI | |
London Stock Exchange | GBX | FBT | FBT LN FBTINAV | ||
London Stock Exchange | GBP | - | FBT LN | ||
London Stock Exchange | USD | FBTU | FBTU LN FBTINAV |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Nasdaq US Biotechnology UCITS ETF | 476 | 0.35% p.a. | Accumulating | Sampling |
Invesco Nasdaq Biotech UCITS ETF | 307 | 0.40% p.a. | Accumulating | Swap-based |
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 35 | 0.35% p.a. | Distributing | Sampling |